References
- Sørensen J, Hetland ML. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2014;1-7. [Epub ahead of print]
- Belge K, Brück J, Ghoreschi K. Advances in treating psoriasis. F1000Prime Rep 2014;6:4
- Langham S, Langham J, Goertz HP, Ratcliffe M. Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: a systematic and critical review. BMC Med Res Methodol 2011;11:32
- Amherd-Hoekstra A, Näher H, Lorenz HM, Enk AH. Psoriatic arthritis: a review. J Dtsch Dermatol Ges 2010;8(5):332-9
- Coates LC, Aslam T, Al Balushi F, et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol 2013;168:802-7
- Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013;72:736-40
- Walsh JA, Callis Duffin K, Krueger GG, Clegg DO. Limitations in Screening Instruments for Psoriatic Arthritis: a Comparison of Instruments in Patients with Psoriasis. J Rheumatol 2013;40:287-93
- Puig L, Fan T, Ding Q, Smith NE. Predictors of biologic treatment of psoriasis: a non-interventional study. Clinicoecon Outcomes Res 2014;6:93-100
- Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509
- Krol M, Brouwer W. How to Estimate Productivity Costs in Economic Evaluations. Pharmacoeconomics 2014;32:335-44
- Moreno JC, Daudén E, Rodriguez-Valverde V, et al. A cost-of-illness study of psoriatic arthritis in Spain. Value Health 2009;12:A437
- Brodszky V, Becsi R, Karpati K, et al. Costs of psoriatic arthritis in Hungary; Results from a cross-sectional survey. Value Health 2009;12:3 Abstract
- Brodszky V, Bálint P, Géher P, et al. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int 2009;30:199-205
- Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65:1175-83
- Olivieri I, de Portu S, Salvarani C, et al. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients within adequate response to conventional therapy. Rheumatology 2008;47:1664-70
- Klimes J, Dolezal T. Indirect costs of moderate and severe forms of psoriasis in Czech Republic: calculation based on self reported questionnaire. Institute of Health Economics and Technology Assessment, ISPOR. Value Health 2010;13:7
- Kvamme MK, Lie E, Kvien TK, Kristiansen IS. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. Rheumatology 2012;51:16181627
- Zhu TY, Tam LS, Leung YY, et al. Socioeconomic Burden of Psoriatic Arthritis in Hong Kong: direct and Indirect Costs and the Influence of Disease Pattern. J Rheumatol 2010;37:1214-20
- World Bank Group. Available from: www.worldbank.org/
- Olivieri I, D’Angelo S, Palazzi C, Padula A. Challenges in economic evaluation of psoriatic arthritis. J Rheumatol 2010;37:1086-8
- Cortesi PA, Scalone L, D’Angiolella L, et al. Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin Exp Rheumatol 2012;30(Suppl 73):S126-31
- Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis a literature review from a global health systems perspective. PT 2010;35(12):680-9
- Inflation calculator. Available from: http://fxtop.com/en/inflation-calculator.php
- OECD. Available from: www.oecd.org/